Analysts think SPRO stock price could increase by 343%
Nov 26, 2024, 12:26 PM
-18.48%
What does SPRO do
Spero Therapeutics, based in Cambridge, Massachusetts, develops treatments for multi-drug resistant infections and rare diseases, with key products including SPR720, tebipenem HBr, and SPR206. The company went public on November 2, 2017, and employs 46 people.
4 analysts think SPRO stock price will increase by 343.48%. The current median analyst target is $5.10 compared to a current stock price of $1.15. The lowest analysts target is $5.05 and the highest analyst target is $5.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
